Author

Martina Imbimbo

Centre Hospitalier Universitaire VaudoisORCID 0000-0003-2521-7540Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 2

Signature Assays, Organisms & Methods

Click to filter · or open tag

Organism:human· 2 Assay:bulk RNA-seq· 1 Research Focus:cell type annotation· 1 Research Focus:cell-cell communication· 1 Research Focus:clustering· 1 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1 Approach:experimental assay· 1

Frequent Co-Authors

Alberto Jesus. ArribasiD· 1 shared Alessandro Ghiringhelli· 1 shared Alex ZadroiD· 1 shared Alexandra Michel· 1 shared Alexandre HarariiD· 1 shared Andrea RinaldiiD· 1 shared Angela OrcurtoiD· 1 shared Aymeric AugeriD· 1 shared

Activity by Year

2024-2025 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 21 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

1 shared paperCancer Biology

Alberto Jesus. ArribasORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Cancer BiologybioRxivPreprintDec 25, 2025

Targeting Aberrant FGFR Signaling with Infigratinib Enhances the Efficacy of BTK/PI3K Inhibitors and Bendamustine in Lymphoma Cells

Giulio Sartori, Alessandro Ghiringhelli, Eleonora Cannas…·Francesco Bertoni

This study shows that combining infigratinib with BTK/PI3K inhibitors or bendamustine improves efficacy in lymphoma cell models, reversing resistance and suggesting FGFR inhibition as a therapeutic strategy.

DOI 10.64898/2025.12.23.695986

humanbulk RNA-seq

𝕏 PostBluesky

Cancer BiologyImmunityPeer-reviewedSep 13, 2024

Tumor-reactive clonotype dynamics underlying clinical response to TIL therapy in melanoma

Johanna Chiffelle, David Barras, Rémy Pétremand…·George Coukos

This study tracks tumor-reactive TIL clonotypes in melanoma patients before and after TIL-ACT to identify factors associated with clinical response.

74 citationstop 1%

humanscRNA-seq

𝕏 PostBluesky